europabio-logoeuropabio-logoeuropabio-logoeuropabio-logo
  • About us
    • Who we are
      • Governance
      • Staff
      • Vacancies
    • What we do
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Cell & Gene Therapies
      • Medicines For Rare Diseases And Children
      • Regulatory Efficiency
      • Biosimilars & Public Procurement
      • Data & Digital
      • Patient Bio-Forum
    • Industrial Biotechnology Council
      • Food, Feed & Nutrition
      • Circular Bioeconomy
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
  • Activities
    • 25 Years of Innovation
    • EFIB 2022
    • European Biotech Week
  • Events
  • Newsroom
    • News & Publications
    • Library
Become a member
✕

European Commission Initiative Improves Information for Patients on Biosimilar Medicines

23/01/2017
PRESS RELEASE
IB1

European Commission Initiative Improves Information for Patients on Biosimilar Medicines

January 23, 2017

• The European Commission Q&A on biosimilar medicines provides a unique resource for patients to enhance understanding and trust in medicines across Europe.
• The document was written to empower patients with reliable information on the use of biosimilar medicines as an alternative therapeutic option.
• For the third year in a row, the European Commission will organise a multi-stakeholder workshop on biosimilar medicines (5 May 2017).

This consensus information on biosimilar medicinal products was drafted for patients together with the European Medicines Agency (EMA), the European Commission and relevant stakeholders: the European Patients Forum (EPF), the European Federation of Crohn's & Ulcerative Colitis Associations (EFCCA), the Standing Committee of European Doctors, European Federation of Pharmaceutical Industries and Associations (EFPIA), European Association for Bio-industries (EuropaBio) and Medicines for Europe.

Biological medicines (including biosimilar medicines) come from living organisms (cells) that have been modified using biotechnology. A biosimilar medicine is developed to be highly similar to an existing biological medicine and has the same biological activity. Biological medicines help treat or prevent many severe diseases including cancers, heart attacks, stroke, diabetes, and autoimmune diseases, such as rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. Biosimilar medicines have significant potential to create competition in the biological medicine market and provide broader affordable access to medicines for patients.

For the third year in a row, the European Commission will organise a multi-stakeholder workshop on biosimilar medicines 5 May 2017. This year, the focus will be on developing a Q&A for healthcare professionals.

European Commission Initiative Improves Information for Patients on Biosimilar Medicines


Download
Share
Alexandra Simionca
Alexandra Simionca

Related posts

17/01/2023

EuropaBio launches SME BioForum in Rare Diseases


Read more
17/01/2023

EuropaBio launches Industry Advisory Group for new Biomanufacturing Platform


Read more
16/01/2023

SwiftPharma joins EuropaBio: pioneering sustainable, scalable and affordable plant-made therapeutic proteins


Read more
19/12/2022

EuropaBio sat down with new member Association of Biotechnological Companies Bioforum, to find out how they champion biotech in central and eastern Europe


Read more

Important links

  • EuropaBio launches SME BioForum in Rare Diseases
  • EuropaBio launches Industry Advisory Group for new Biomanufacturing Platform

Categories in our Newsroom

Search by tags

  • Innovation
  • Excellence
  • Science
  • ATMPs
  • Healthcare Biotech
  • Industrial Biotech
  • Investment
  • EuropaBio
  • EFIB
  • Regulation
  • Rare Diseases
  • COVID-19
  • Members
  • Cancer
  • Patients
  • Patient BioForum
  • Gene & Cell Therapies
  • Accessibility
  • Intellectual Property
  • Pharmaceutical Strategy for Europe

Subscribe for our newsletter

Subscribe to the EuropaBio newsletter to receive the latest news and developments in the Biotech sector!


Subscribe
EuropaBio-Logo-White

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 2600 biotech companies, 2300 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2023 Europabio. All Rights Reserved. Designed by EYAS
Become a member